"Safety and tolerability" of a vaccine is tested in phase I on a small group of volunteers.
The human testing of the "molecular clamp" vaccine candidate, to start on today, follows encouraging results from animal testing trials conducted in the Netherlands. The focus will also be on ramping up the vaccine's production.
Chutitorn Ketloy, a research team member, said macaques which were vaccinated between May and June seem to have developed immunity against COVID-19, with their antibody levels reaching up to 5,120 after receiving the second dose.
The Thai study will begin its human trials as early as September and will be among the first done outside high-income countries.
However, there was no further information on when this vaccine would enter the commercial production stage.
Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russian Federation showed that they were developing immunity to the coronavirus.
Researchers at the Sechenov University said the study involved 38 volunteers in total and that the vaccine was found to be safe. They will soon be discharged from the facilities in two batches - Wednesday, 15 July and five days after that on Monday, 20 July. The volunteers, aged 18 to 65, will be monitored for six more months after their release. This is a so-called systemic and local post-vaccine reaction which is mild and disappears on its own without any additional measures.
The Russian Health Ministry had sanctioned the trial on June 16.
TASS reported that "Both the first and second groups were forming an immune response after injections of the vaccine".
A report by the TASS news agency of Russian Federation on July 10 said the phase I clinical trials would end on July 15, while the second phase would begin on July 13.
Around seven Indian firms are now working on coronavirus vaccines.
Till now, only the Bharat Biotech International Ltd and the Zydus Cadila pharmaceutical companies' indigenously developed vaccine prototypes have got an approval for the human trials from the Drugs Controller General of India.